Literature DB >> 20606435

The effect of the APOE-epsilon4 allele and ACE-I/D polymorphism on cognition during a two-year follow-up in first-ever stroke patients.

A M J J Bour1, S M C Rasquin, L Baars, M P J van Boxtel, P J Visser, M Limburg, F R J Verhey.   

Abstract

BACKGROUND: Cognitive impairment is commonly observed after stroke and has a negative impact on survival and rehabilitation. Some stroke patients deteriorate in cognitive functioning whereas others do not. Environmental and demographic risk factors cannot fully explain this. There is growing evidence that a genetic predisposition plays a role in the pathogenesis of post-stroke cognitive decline.
OBJECTIVE: To study the influence of the APOE-epsilon4 allele and the ACE-I/D polymorphism on cognitive functioning after stroke.
METHODS: We included 194 first-ever stroke patients of whom information about APOE genotyping and ACE-I/D polymorphism was available in 92 and 129 patients, respectively. Patients were cognitively assessed at 1, 6, 12 and 24 months after the event. Linear mixed models with slope estimates were used to study the influence of the APOE-epsilon4 allele and the ACE-I/D polymorphism on the MMSE score, CAMCOG, executive functioning, psychomotor speed, and verbal memory function during follow-up.
RESULTS: Patients carrying the APOE-epsilon4 allele more often suffered a lacunar infarction than non-carriers. The APOE-epsilon4 allele had no effect on cognitive functioning during the follow-up. ACE-DD homozygosity was associated with a worse performance in executive functioning compared to patients with neither an APOE-epsilon4 allele nor the ACE-DD genotype. There was no interaction between the APOE-epsilon4 allele and the ACE-DD phenotype in the prediction of cognitive decline.
CONCLUSION: The ACE-DD genotype may be associated with post-stroke cognitive decline while the APOE-epsilon4 allele is not. Further research is needed to examine the role of genetic risk factors for post-stroke cognitive decline and to determine why some patients deteriorate cognitively after stroke but others do not. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20606435     DOI: 10.1159/000314678

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  5 in total

Review 1.  A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward.

Authors:  Michaël E Belloy; Valerio Napolioni; Michael D Greicius
Journal:  Neuron       Date:  2019-03-06       Impact factor: 17.173

2.  Biological and imaging predictors of cognitive impairment after stroke: a systematic review.

Authors:  Barbara Casolla; François Caparros; Charlotte Cordonnier; Stéphanie Bombois; Hilde Hénon; Régis Bordet; Francesco Orzi; Didier Leys
Journal:  J Neurol       Date:  2018-10-22       Impact factor: 4.849

3.  Screening for cognitive decline following single known stroke using the Mini-Mental State Examination.

Authors:  David B Arciniegas; Gregory F Kellermeyer; Nancy M Bonifer; Kristin M Anderson-Salvi; C Alan Anderson
Journal:  Neuropsychiatr Dis Treat       Date:  2011-04-13       Impact factor: 2.570

Review 4.  Genetic determinants of swallowing impairment, recovery and responsiveness to treatment.

Authors:  Alicja Raginis-Zborowska; Neil Pendleton; Shaheen Hamdy
Journal:  Curr Phys Med Rehabil Rep       Date:  2016-08-08

Review 5.  Post-stroke dementia - a comprehensive review.

Authors:  Milija D Mijajlović; Aleksandra Pavlović; Michael Brainin; Wolf-Dieter Heiss; Terence J Quinn; Hege B Ihle-Hansen; Dirk M Hermann; Einor Ben Assayag; Edo Richard; Alexander Thiel; Efrat Kliper; Yong-Il Shin; Yun-Hee Kim; SeongHye Choi; San Jung; Yeong-Bae Lee; Osman Sinanović; Deborah A Levine; Ilana Schlesinger; Gillian Mead; Vuk Milošević; Didier Leys; Guri Hagberg; Marie Helene Ursin; Yvonne Teuschl; Semyon Prokopenko; Elena Mozheyko; Anna Bezdenezhnykh; Karl Matz; Vuk Aleksić; DafinFior Muresanu; Amos D Korczyn; Natan M Bornstein
Journal:  BMC Med       Date:  2017-01-18       Impact factor: 8.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.